2023-03-23 08:44:04 ET
- Solid Biosciences press release ( NASDAQ: SLDB ): Q4 Net loss of $15.2M
-
Solid had $213.7 million in cash, cash equivalents, and available-for-sale securities as of December 31, 2022, compared to $207.8 million as of December 31, 2021. This financial position resulted from streamlined operating activities, the acquisition of AavantiBio, and a $75.0 million private placement. The Company expects that its cash, cash equivalents, and available-for-sale securities will enable it to fund key strategic priorities into 2025.
For further details see:
Solid Biosciences reports Q4 results